Full Breakdown
FDA Approves Leucovorin for Rare Genetic Condition, Not Autism
3/12/2026, 11:53:42 AM
FDA's Narrow Approval of Leucovorin
On March 10, 2026, the U.S. Food and Drug Administration (FDA) approved leucovorin, a synthetic form of vitamin B9, for the treatment of cerebral folate deficiency (CFD), a rare genetic condition affecting fewer than one in a million people. This decision marks a significant departure from the Trump administration's earlier claims that the drug could serve as a treatment for autism, a broader and more common diagnosis. During a September 2025 press conference, FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr. suggested that leucovorin could benefit "hundreds of thousands" of children with autism, linking it to potential improvements in symptoms.
Background and Context
The FDA's recent approval was based on a systematic review of existing literature rather than clinical trials, as conducting such trials for the ultra-rare condition is challenging. The agency found insufficient evidence to support leucovorin's efficacy for autism, stating, "Right now, we don't have sufficient data to say that we could establish efficacy for autism more broadly." This conclusion follows a retraction of a significant study that had previously suggested a link between leucovorin and improvements in autism symptoms.
Impact on Families and Medical Community
The FDA's decision has left many families feeling disillusioned. Parents like Meagan Johnson, whose son has autism and was prescribed leucovorin, expressed frustration over the administration's earlier claims. Johnson stated, "I'm tired of them coming out and prematurely saying things without the information to back it." The surge in interest following the September announcement led to a 71% increase in prescriptions for leucovorin among children, complicating access for those who genuinely need it.
Experts in the field, including Dr. Alycia Halladay from the Autism Science Foundation, have cautioned against the use of leucovorin for autism, emphasizing that the drug's safety and efficacy for this purpose remain unproven. The American Academy of Pediatrics has also advised against its routine use in autistic children, citing a lack of robust evidence.
Criticism and Opposition
Critics have pointed out the dangers of politicizing medical treatments. David Mandell, a professor of psychiatry at the University of Pennsylvania, remarked, "Families deserve better than that. They deserve more careful science." The FDA's recent announcement has been described as a necessary correction to the misleading claims made by the Trump administration, which had raised unrealistic hopes among families seeking solutions for autism.
What's Next for Leucovorin?
While the FDA has approved leucovorin for CFD, the agency remains open to further research on its potential applications for autism. However, the path forward is uncertain, as funding for large-scale clinical trials in autism is limited. The FDA's decision has prompted discussions about the need for rigorous scientific evaluation before any broader claims can be made regarding leucovorin's effectiveness for autism.
Verbatim Quotes
- “Right now, we don't have sufficient data to say that we could establish efficacy for autism more broadly,” — Senior FDA Official
- “I’m tired of them coming out and prematurely saying things without the information to back it.” — Meagan Johnson, Parent
- “Families deserve better than that. They deserve more careful science. They deserve more accurate information.” — David Mandell, Professor of Psychiatry
The FDA's decision to limit leucovorin's approval to a rare genetic condition rather than autism underscores the importance of evidence-based medicine and the need for careful communication in public health matters.
